Clinical Trial Update: Clinical Lot Consistency for RSVpreF in a Population of Healthy Adults 18 to ≤49 Years of Age [Phase 3]

View source ↗

Summary

Phase 3 trial update on lot-to-lot consistency for an RSV vaccine (RSVpreF) in healthy adults aged 18 to 49.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Disease

Drugs mentioned

• RSVpreF

Snippet

Sponsor: Pfizer | Conditions: RSV | Phase 3 | Status: COMPLETED | Results posted: 2023-04-12